ABSTRACT
Waon therapy has been developed by Prof Tei, and currently been approved as one of advanced medical care in Japanese governmental insurance system since 2013. We are now conducting a multicenter randomized study for the establishment of efficacy and safety of Waon therapy. As one of institutes participating in the multicenter trial, I will present data from our hospital for the efficacy and safety issues of Waon therapy. We preliminarily observed that Waon therapy reduced heart rate and cardiothoracic ratio with significant improvement of 6 minutes’ walk distance. No serious adverse event was observed. Once the study concludes, we hope that Waon therapy can be reimbursed by insurance.
ABSTRACT
Waon therapy has been developed by Prof Tei, and currently been approved as one of advanced medical care in Japanese governmental insurance system since 2013. We are now conducting a multicenter randomized study for the establishment of efficacy and safety of Waon therapy. As one of institutes participating in the multicenter trial, I will present data from our hospital for the efficacy and safety issues of Waon therapy. We preliminarily observed that Waon therapy reduced heart rate and cardiothoracic ratio with significant improvement of 6 minutes’ walk distance. No serious adverse event was observed. Once the study concludes, we hope that Waon therapy can be reimbursed by insurance.
ABSTRACT
PURPOSE: The aim of this study was to evaluate the validity and reliability of the Seattle Angina Questionnaire, Japanese version (SAQ-J) as a disease-specific health outcome scale in patients with coronary artery disease. METHODS: Patients with coronary artery disease were recruited from a university hospital in Tokyo. The patients completed self-administered questionnaires, and medical information was obtained from the subjects' medical records. Face validity, concurrent validity evaluated using Short Form 36 (SF-36), known group differences, internal consistency, and test-retest reliability were statistically analyzed. RESULTS: A total of 354 patients gave informed consent, and 331 of them responded (93.5%). The concurrent validity was mostly supported by the pattern of association between SAQ-J and SF-36. The patients without chest symptoms showed significantly higher SAQ-J scores than did the patients with chest symptoms in 4 domains. Cronbach's alpha ranged from .51 to .96, meaning that internal consistency was confirmed to a certain extent. The intraclass correlation coefficient of most domains was higher than the recommended value of 0.70. The weighted kappa ranged from .24 to .57, and it was greater than .4 for 14 of the 19 items. CONCLUSIONS: The SAQ-J could be a valid and reliable disease-specific scale in some part for measuring health outcomes in patients with coronary artery disease, and requires cautious use.